Drugs / HP802-247
last change Nov 2017 re-read 2 minutes ago

HP802-247

Cell therapy

Developed for
ulcer of lower limbs · epidermolysis bullosa dystrophica · ulcer disease
Investigated by
Healthpoint · Atlantic Health System · Smith & Nephew, Inc.

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01190865 Sep → Dec 2010 Healthpoint Completed No outcome recorded
Phase 24 trials
Phase 2 NCT02154087 Jul 2014 → Jul 2015 ulcer of lower limbs Healthpoint Terminated No outcome recorded
Phase 2 NCT01528306 Mar 2012 → Mar 2013 epidermolysis bullosa dystrophica Healthpoint Withdrawn No outcome recorded
Phase 2 NCT01320605 Mar 2011 → Jun 2012 ulcer of lower limbs Atlantic Health System Unknown No outcome recorded
Phase 2 NCT00852995 Feb 2009 → Apr 2011 ulcer of lower limbs Healthpoint Completed No outcome recorded
Phase 33 trials
Phase 3 NCT01853384 Nov 2013 → Dec 2014 ulcer disease, ulcer of lower limbs Healthpoint Terminated No outcome recorded
Phase 3 NCT01737762 Nov 2012 → Nov 2015 ulcer of lower limbs Healthpoint Completed No outcome recorded
Phase 3 NCT01656889 Aug 2012 → Dec 2014 ulcer of lower limbs Healthpoint Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01359735 Comparator May → Nov 2011 skin cancer Healthpoint Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as HP802-247 “Closure of VLUs after treatment with HP802-247, an allogeneic living cell therapy consisting of growth-arrested human keratinocytes and fibroblasts, vs standard therapy with...” PMID 29037354 Nov 2017
9

“HP-802-247” NCT01656889

NCT02154087

NCT01190865

NCT01853384

NCT01737762

NCT00852995

NCT01320605

NCT01359735

NCT01528306

Modality Cell therapy “HP802-247 is a novel spray-applied cell therapy containing growth-arrested allogeneic neonatal keratinocytes and fibroblasts.” PMID 22863328 Aug 2012
Route Topical “when applied to chronic venous leg ulcers” PMID 22863328 Aug 2012